… shown that cyclooxygenase 2 (COX2) is involved in tumour … Selective inhibitors of COX2
(coxibs) block tumour growth … of celecoxib in the inhibition of blood-vessel formation, tumour …

… A prospective phase I-II trial of the cyclooxygenase-2 inhibitor Celecoxib in patients with
carcinoma of the cervix with biomarker assessment of the tumor microenvironment. Int J Radiat …

… of PGE 2 in the lung tumor microenvironment, thereby promoting the malignant phenotype.
… -2 inhibitor celecoxib significantly decreased tumor growth in the Lewis lung carcinoma (LLC…

… factor receptor, cell cycle, histone deacetylases, cyclooxygenase-2 (COX-2), or … celecoxib
retrieved (109 patients) [29], [30], [31], both of them described the results of phase I/II trials…

… Within the tumor microenvironment, the maintenance of a … for some evaluation of
cyclooxygenase-2 specific inhibitors (… Thomas Lynch: We are seeing trial designs in which …

… and cyclooxygenase‑2 have been reported as possible biomarkers in cervical cancer. Novel
… cancer (51,52), as shown using a COX-2 inhibitor, celecoxib (53). Associations between the …

… and tumor size; (4.1) the assay used to measure biomarker expression … Cyclooxygenase-2
is an important enzyme in the conversion of … However, celecoxib in combination with standard …

… of patients discontinued celecoxib due to toxicity. The author concluded that celecoxib at 400
… Another phase I-II trial using celecoxib as a radiosensitizer was performed by Herrera et al. …

… has an ongoing phase I/II study of celecoxib with irradiation … Secondary objectives are to
assess select biomarkers, as … KS: High cyclooxygenase-2 expression in stage IB cervical cancer …

… that celecoxib is effective in the advanced stages of cancer. … survival of patients in prostate,
cervical, skin, and bladder cancer. … Phase I/II, III/IV clinical trials in collaboration with NCI and …